RS51081B - Nova sinergistička kombinacija koja uključuje roflumilast i formoterol - Google Patents

Nova sinergistička kombinacija koja uključuje roflumilast i formoterol

Info

Publication number
RS51081B
RS51081B YUP-2005/0382A YUP20050382A RS51081B RS 51081 B RS51081 B RS 51081B YU P20050382 A YUP20050382 A YU P20050382A RS 51081 B RS51081 B RS 51081B
Authority
RS
Serbia
Prior art keywords
formoterol
roflumilast
administered
acceptable salt
pharmacologically acceptable
Prior art date
Application number
YUP-2005/0382A
Other languages
English (en)
Serbian (sr)
Inventor
Degenhard Dr. Marx
Norbert dr. KOLASSA
Christian Dr. Weimar
Daniela Dr. Bundschuh
Rolf Dr. Beume
Original Assignee
Nycomed Gmbh.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Gmbh. filed Critical Nycomed Gmbh.
Priority to MEP-2008-782A priority Critical patent/ME00489B/me
Publication of RS20050382A publication Critical patent/RS20050382A/sr
Publication of RS51081B publication Critical patent/RS51081B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
YUP-2005/0382A 2002-11-27 2003-11-26 Nova sinergistička kombinacija koja uključuje roflumilast i formoterol RS51081B (sr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MEP-2008-782A ME00489B (me) 2002-11-27 2003-11-26 NOVA SINERGIČKA KOMBINACIJA KOJA UKLJUČUJE ROFLUMILAST l FERMOTEROL

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02026505 2002-11-27
PCT/EP2003/013275 WO2004047829A1 (en) 2002-11-27 2003-11-26 New synergistic combination comprising roflumilast and formoterol

Publications (2)

Publication Number Publication Date
RS20050382A RS20050382A (sr) 2007-08-03
RS51081B true RS51081B (sr) 2010-10-31

Family

ID=32338002

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-2005/0382A RS51081B (sr) 2002-11-27 2003-11-26 Nova sinergistička kombinacija koja uključuje roflumilast i formoterol

Country Status (31)

Country Link
US (1) US20060142308A1 (OSRAM)
EP (1) EP1567139B1 (OSRAM)
JP (1) JP2006508994A (OSRAM)
KR (1) KR101071798B1 (OSRAM)
CN (1) CN100346777C (OSRAM)
AT (1) ATE399543T1 (OSRAM)
AU (1) AU2003292120B2 (OSRAM)
BR (1) BR0316451A (OSRAM)
CA (1) CA2506962C (OSRAM)
CO (1) CO5690570A2 (OSRAM)
CY (1) CY1110369T1 (OSRAM)
DE (1) DE60321953D1 (OSRAM)
DK (1) DK1567139T3 (OSRAM)
EA (1) EA009935B1 (OSRAM)
ES (1) ES2309357T3 (OSRAM)
HR (1) HRP20050579B1 (OSRAM)
IL (1) IL168308A (OSRAM)
IS (1) IS2575B (OSRAM)
MA (1) MA27539A1 (OSRAM)
ME (1) ME00489B (OSRAM)
MX (1) MXPA05005437A (OSRAM)
NO (1) NO334247B1 (OSRAM)
NZ (1) NZ540659A (OSRAM)
PL (1) PL216752B1 (OSRAM)
PT (1) PT1567139E (OSRAM)
RS (1) RS51081B (OSRAM)
SI (1) SI1567139T1 (OSRAM)
TN (1) TNSN05131A1 (OSRAM)
UA (1) UA83018C2 (OSRAM)
WO (1) WO2004047829A1 (OSRAM)
ZA (1) ZA200503308B (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
DE602004023921D1 (de) 2003-03-10 2009-12-17 Nycomed Gmbh Neues verfahren zur herstellung vonroflumilast
US8663694B2 (en) * 2005-03-16 2014-03-04 Takeda Gmbh Taste masked dosage form containing roflumilast
DE102005030733A1 (de) * 2005-07-01 2007-01-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff
EP2359826B1 (en) * 2006-07-05 2013-10-30 Takeda GmbH Combination of HMG-COA reductase inhibitor rosuvastatin with a phosphodiesterase 4 inhibitor, such as roflumilast, roflumilast-N-oxide for the treatment of inflammatory pulmonary diseases
WO2013077830A1 (en) * 2011-11-25 2013-05-30 Mahmut Bilgic Synergistilly active combinations of roflumilast and carmoterol
US20130172303A1 (en) * 2012-01-03 2013-07-04 Forest Laboratories Holdings Ltd. Roflumilast compositions for the treatment of copd
CN110403922A (zh) 2013-01-28 2019-11-05 理森制药股份公司 通过吸入罗氟司特n-氧化物治疗自身免疫、呼吸和/或炎性病症的方法
CN104800214A (zh) * 2014-01-27 2015-07-29 成都英诺新科技有限公司 一种罗氟司特吸入气雾剂复方及制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
SI0706513T1 (en) * 1993-07-02 2002-10-31 Altana Pharma Ag Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
AU734122B2 (en) * 1997-02-17 2001-06-07 Takeda Gmbh Compositions for the treatment of ARDS or IRDS containing 3-(cyclopropylmethoxy)-n-(3,5-dichloro-4-pyridinyl)-4- (difluoromethoxy)benzamide and lung surfactant
SI0975347T1 (sl) * 1997-02-28 2008-08-31 Nycomed Gmbh Sinergistična kombinacija PDE inhibitorjev in agonistov adenilat ciklaze oziroma agonistov gvanil ciklize
US6624181B1 (en) * 1997-02-28 2003-09-23 Altana Pharma Ag Synergistic combination
HUP0103160A3 (en) * 1998-08-26 2002-11-28 Smithkline Beecham Corp Pharmaceutical compositions for treating pulmonary diseases containing pde4 inhibitor
US6303145B2 (en) * 1999-05-10 2001-10-16 Sepracor Inc. (S,R) formoterol methods and compositions
HU229439B1 (hu) * 1999-08-21 2013-12-30 Takeda Gmbh Roflumilast és salmeterol szinergetikus kombinációja
GB0103630D0 (en) * 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
WO2002076933A1 (en) * 2001-03-22 2002-10-03 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists
US7291608B2 (en) * 2001-04-30 2007-11-06 Glaxo Group Limited Anti-inflammatory 17.β.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.α

Also Published As

Publication number Publication date
ES2309357T3 (es) 2008-12-16
UA83018C2 (uk) 2008-06-10
WO2004047829A8 (en) 2005-06-30
EP1567139B1 (en) 2008-07-02
EA200500774A1 (ru) 2005-12-29
US20060142308A1 (en) 2006-06-29
NO334247B1 (no) 2014-01-20
DE60321953D1 (de) 2008-08-14
TNSN05131A1 (en) 2007-05-14
DK1567139T3 (da) 2008-11-03
HK1081861A1 (en) 2006-05-26
IS7898A (is) 2005-06-20
CN100346777C (zh) 2007-11-07
AU2003292120A1 (en) 2004-06-18
CO5690570A2 (es) 2006-10-31
ME00489B (me) 2011-10-10
CA2506962A1 (en) 2004-06-10
PL377732A1 (pl) 2006-02-06
WO2004047829A1 (en) 2004-06-10
JP2006508994A (ja) 2006-03-16
KR101071798B1 (ko) 2011-10-11
MA27539A1 (fr) 2005-09-01
CY1110369T1 (el) 2015-04-29
BR0316451A (pt) 2005-10-11
NO20052999L (no) 2005-06-17
PL216752B1 (pl) 2014-05-30
PT1567139E (pt) 2008-10-01
IL168308A (en) 2010-12-30
SI1567139T1 (sl) 2008-12-31
IS2575B (is) 2010-02-15
EP1567139A1 (en) 2005-08-31
MXPA05005437A (es) 2005-08-03
HRP20050579A2 (hr) 2006-04-30
ATE399543T1 (de) 2008-07-15
ZA200503308B (en) 2006-11-29
EA009935B1 (ru) 2008-04-28
RS20050382A (sr) 2007-08-03
CA2506962C (en) 2012-01-03
CN1713903A (zh) 2005-12-28
NZ540659A (en) 2007-05-31
HRP20050579B1 (hr) 2014-01-31
KR20050085104A (ko) 2005-08-29
AU2003292120B2 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
US6455524B1 (en) Medicament compositions based on anticholinergically-effective compounds and beta-mimetics
PL200923B1 (pl) Lek zawierający inhibitor PDE w połączeniu z agonistą receptoraß₂ -adrenergicznego oraz zastosowanie połączenia roflumilastu i salmeterolu
CA2550841C (en) Novel combination of anticholinergic and .beta. mimetics for the treatment of respiratory diseases
KR20050104367A (ko) 타 활성제와 결합하여 장기 효능을 지속하는 베타2-동근으로 구성되는 약물
SK285884B6 (sk) Kombinovaný prípravok formoterolu a tiotrópiovej soli, jeho použitie a farmaceutická súprava, ktoráho obsahuje
CA2588042A1 (en) Compositions and methods for pulmonary conditions
RS51081B (sr) Nova sinergistička kombinacija koja uključuje roflumilast i formoterol
RS51082B (sr) Sinergistička kombinacija koja uključuje roflumilas i (r.r.) -formoterol
HK1081861B (en) New synergistic combination comprising roflumilast and formoterol